Determination of HER2 amplification in primary breast cancer using dual-colour chromogenic in situ hybridization is comparable to fluorescence in situ hybridization: A European multicentre study involving 168 specimens

Histopathology

Volumn 56, Issue 4, 2010, Pages 472-480

  García Caballero, Tomás ^a   Grabau, Dorthe ^b   Green, Andrew R ^c   Gregory, John ^d   Schad, Arno ^e   Kohlwes, Elke ^e   Ellis, Ian O ^c   Watts, Sarah ^c   Mollerup, Jens ^f  

^a UNIVERSITY OF SANTIAGO DE COMPOSTELA   (Spain)

^b LUND UNIVERSITY HOSPITAL   (Sweden)

^c UNIVERSITY OF NOTTINGHAM   (United Kingdom)

^d UNIVERSITY HOSPITALS BIRMINGHAM NHS FOUNDATION TRUST   (United Kingdom)

^e UNIVERSITY MEDICAL CENTER MAINZ   (Germany)

^f AGILENT TECHNOLOGIES   (United States)

Author keywords

Breast cancer; CEN 17; CISH; FISH; HER2; HER2 amplification; In situ hybridization

Indexed keywords

ARTICLE; BREAST CANCER; CENTROMERE; CHROMOGENIC IN SITU HYBRIDIZATION; CONTROLLED STUDY; EUROPE; FLUORESCENCE IN SITU HYBRIDIZATION; HUMAN; HUMAN TISSUE; IN SITU HYBRIDIZATION; INTERMETHOD COMPARISON; ONCOGENE NEU; PRIMARY TUMOR; PRIORITY JOURNAL; SCORING SYSTEM;

BREAST NEOPLASMS; CENTROMERE; COLOR; EUROPE; FEMALE; GENE AMPLIFICATION; GENES, ERBB-2; HUMANS; HYBRIDIZATION, GENETIC; IN SITU HYBRIDIZATION; IN SITU HYBRIDIZATION, FLUORESCENCE; MICROSCOPY; MICROSCOPY, FLUORESCENCE; NEOPLASMS;

EID: 77949591945     PISSN: 03090167     EISSN: 13652559     Source Type: Journal    
DOI: 10.1111/j.1365-2559.2010.03503.x     Document Type: Article

References (27)

1. Bhargava R, Lal P, Chen B. Chromogenic in situ hybridization for the detection of HER-2/neu gene amplification in breast cancer with an emphasis on tumors with borderline and low-level amplification: does it measure up to fluorescence in situ hybridization? Am. J. Clin. Pathol. 2005 123 237 243.
2. Arnould L, Denoux Y, MacGrogan G et al. Agreement between chromogenic in situ hybridisation (CISH) and FISH in the determination of HER2 status in breast cancer. Br. J. Cancer 2003 88 1587 1591.
3. Lambros MB, Natrajan R, Reis-Filho JS. Chromogenic and fluorescent in situ hybridization in breast cancer. Hum. Pathol. 2007 38 1105 1122.
4. Ross JS, Fletcher JA, Bloom KJ et al. Targeted therapy in breast cancer: the HER-2/neu gene and protein. Mol. Cell Proteomics 2004 3 379 398.
5. Laakso M, Tanner M, Isola J. Dual-colour chromogenic in situ hybridization for testing of HER-2 oncogene amplification in archival breast tumours. J. Pathol. 2006 210 3 9.
6. Kim G, Oh Y. Chromogenic in situ hybridization analysis of HER-2/neu status in cytological samples of breast carcinoma. Cytopathology 2004 15 315 320.
7. Tanner M, Gancberg D, Di LA et al. Chromogenic in situ hybridization: a practical alternative for fluorescence in situ hybridization to detect HER-2/neu oncogene amplification in archival breast cancer samples. Am. J. Pathol. 2000 157 1467 1472.
8. Wolff AC, Hammond ME, Schwartz JN et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J. Clin. Oncol. 2007 25 118 145.
9. Slamon DJ, Godolphin W, Jones LA et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 1989 244 707 712.
10. Piccart-Gebhart MJ, Procter M, Leyland-Jones B et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N. Engl. J. Med. 2005 353 1659 1672.
11. Slamon DJ, Leyland-Jones B, Shak S et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N. Engl. J. Med. 2001 344 783 792.
12. Romond EH, Perez EA, Bryant J et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N. Engl. J. Med. 2005 353 1673 1684.
13. Koch GG, Landis JR, Freeman JL, Freeman DH Jr., Lehnen RC. A general methodology for the analysis of experiments with repeated measurement of categorical data. Biometrics 1977 33 133 158.
14. Cuadros M, Villegas R. Systematic review of HER2 breast cancer testing. Appl. Immunohistochem. Mol. Morphol. 2009 17 1 7.
15. Cameron D, Casey M, Press M et al. A phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: updated efficacy and biomarker analyses. Breast Cancer Res. Treat. 2008 112 533 543.
16. De Laurentiis M, Arpino G, Massarelli E et al. A meta-analysis on the interaction between HER-2 expression and response to endocrine treatment in advanced breast cancer. Clin. Cancer Res. 2005 11 4741 4748.
17. Rastelli F, Crispino S. Factors predictive of response to hormone therapy in breast cancer. Tumori 2008 94 370 383.
18. Bilous M, Dowsett M, Hanna W et al. Current perspectives on HER2 testing: a review of national testing guidelines. Mod. Pathol. 2003 16 173 182.
19. Hanna WM, Kwok K. Chromogenic in-situ hybridization: a viable alternative to fluorescence in-situ hybridization in the HER2 testing algorithm. Mod. Pathol. 2006 19 481 487.
20. Gong Y, Gilcrease M, Sneige N. Reliability of chromogenic in situ hybridization for detecting HER-2 gene status in breast cancer: comparison with fluorescence in situ hybridization and assessment of interobserver reproducibility. Mod. Pathol. 2005 18 1015 1021.
21. Dandachi N, Dietze O, Hauser-Kronberger C. Chromogenic in situ hybridization: a novel approach to a practical and sensitive method for the detection of HER2 oncogene in archival human breast carcinoma. Lab. Invest. 2002 82 1007 1014.
22. Isola J, Tanner M, Forsyth A, Cooke TG, Watters AD, Bartlett JM. Interlaboratory comparison of HER-2 oncogene amplification as detected by chromogenic and fluorescence in situ hybridization. Clin. Cancer Res. 2004 10 4793 4798.
23. Saez A, Andreu FJ, Segui MA et al. HER-2 gene amplification by chromogenic in situ hybridisation (CISH) compared with fluorescence in situ hybridisation (FISH) in breast cancer - a study of two hundred cases. Breast 2006 15 519 527.
24. Di Palma S, Collins N, Faulkes C et al. Chromogenic in situ hybridisation (CISH) should be an accepted method in the routine diagnostic evaluation of HER2 status in breast cancer. J. Clin. Pathol. 2007 60 1067 1068.
25. van de Vijver M, Bilous M, Hanna W et al. Chromogenic in situ hybridisation for the assessment of HER2 status in breast cancer: an international validation ring study. Breast Cancer Res. 2007 9 R68.
26. Vocaturo A, Novelli F, Benevolo M et al. Chromogenic in situ hybridization to detect HER-2/neu gene amplification in histological and ThinPrep-processed breast cancer fine-needle aspirates: a sensitive and practical method in the trastuzumab era. Oncologist 2006 11 878 886.
27. Hoff K, Jørgensen JT, Müller S, Røngaard E, Rasmussen O, Schønau A Visualization of FISH Probes by dual-color chromogenic in situ hybridization. Am. J. Clin. Pathol. 2009 133 205 211.